BIND Therapeutics and AstraZeneca Publish Preclinical Data Illustrating ACCURINS® Ability to Utilize Proprietary Hydrophobic Ion Pairing to Increase Biodistribution to Tumor Sites of Molecularly Targeted Agents
CAMBRIDGE, Mass.–(BUSINESS WIRE)– BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing innovative therapeutics called ACCURINS®, today announced the publication of data highlighting the ability of ACCURIN polymeric nanoparticle technology to utilize hydrophobic ion pairing and improve the therapeutic index of a molecularly targeted anti-cancer drug. Previous efforts with nanotechnology have focused almost exclusively on encapsulating chemotherapy payloads; the publication describes one of the first efforts to apply nanotechnology to a molecular targeted agent. Results highlight the potential for ACCURINS® to control release kinetics and provide increased concentration of an aurora B kinase inhibitor, AZD2811, at tumor sites resulting in prolonged pharmacodynamic effects, superior tumor growth inhibition and a reduction in on-target but off-tissue toxicity. These data were published in the February 10, 2016 issue of Science Translational Medicine.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160210006458/en/